<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02916979</url>
  </required_header>
  <id_info>
    <org_study_id>D16127</org_study_id>
    <nct_id>NCT02916979</nct_id>
  </id_info>
  <brief_title>Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG</brief_title>
  <acronym>FluBuATG</acronym>
  <official_title>A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is examining a chemotherapy regimen and immune suppressive medications in the&#xD;
      setting of an allogeneic stem cell transplant. A pilot clinical trial to characterize the&#xD;
      incidence, prevalence and function of myeloid-derived suppressor cells (MDSCs) and immune&#xD;
      checkpoint regulators (V-domain Ig Suppressor of T-cell Activation [VISTA], cytotoxic&#xD;
      T-lymphocyte- associated protein 4 [CTLA-4], programmed death-ligand 1 [PD-L1]) during early&#xD;
      immune recovery following an allogeneic stem cell transplant. The site will use a&#xD;
      myeloablative regimen of fludarabine with busulfan, adopted from CALGB 100801, to define&#xD;
      clinical endpoints, including engraftment, 100 day survival and one year survival (Objective&#xD;
      #1). The site will characterize the incidence, prevalence and function of MDSCs and immune&#xD;
      checkpoint regulators in patients' blood and bone marrow following transplantation (Objective&#xD;
      #2). The site will correlate these laboratory results with clinical outcomes and the&#xD;
      incidence of graft-versus-host disease (GVHD). As an exploratory aim, in those patients&#xD;
      experiencing GVHD and requiring treatment, the site will define the MDSCs frequency and&#xD;
      checkpoint regulator expression and correlate these results with the patient's response to&#xD;
      GVHD therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who are surviving at 100-Days post-transplant</measure>
    <time_frame>100 Days</time_frame>
    <description>100-Day survival of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to marrow engraftment</measure>
    <time_frame>100 Days</time_frame>
    <description>Time to marrow engraftment (defined as absolute neutrophil count &gt; 500/mm3 and platelets &gt; 20,000/mcl for three consecutive days (count first day as engraftment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing all subjects' response to treatment at 100 days post-transplant</measure>
    <time_frame>100 Days</time_frame>
    <description>Response to treatment at 100 days using standard international response criteria, based on CIBMTR definitions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing all subjects' response to treatment at 1 year post-transplant</measure>
    <time_frame>365 Days</time_frame>
    <description>Response to treatment at one year using standard international response criteria, based on CIBMTR definitions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing all subjects' survival at 1 year post-transplant</measure>
    <time_frame>365 Days</time_frame>
    <description>One year survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing the mortality rate of patients in the first 100 days post-transplant</measure>
    <time_frame>100 Days</time_frame>
    <description>Treatment-related mortality in the first 100 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing the number of treatment-related adverse events</measure>
    <time_frame>365 Days</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collecting the incidents of GvHD experienced by patients post-transplant</measure>
    <time_frame>365 Days</time_frame>
    <description>Incidence of acute and chronic GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing the donor-chimerism at 30, 60 and 90 days post-transplant</measure>
    <time_frame>30, 60, and 90 Days</time_frame>
    <description>Donor-recipient chimerism following transplant at Days 30, 60 and 90.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Leukemia, Lymphoid</condition>
  <condition>Leukemia, Myeloid</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelofibrosis</condition>
  <condition>Lymphoma, Malignant</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Conditioning Regimen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fludarabine, Busulfan, Rabbit ATG, Methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine: 30 mg/m2 daily for 5 days</description>
    <arm_group_label>Conditioning Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan: 100 mg/m2 daily for 4 days</description>
    <arm_group_label>Conditioning Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabbit ATG</intervention_name>
    <description>Rabbit ATG:&#xD;
Related donors: 1.5 mg/kg daily x 2 days (on days -6 and -5) Unrelated donors: 1.5 mg/kg on day - 6 2 mg/kg on day -5 2.5 mg/kg on day -4</description>
    <arm_group_label>Conditioning Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate:&#xD;
Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11</description>
    <arm_group_label>Conditioning Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age less than or equal to 75 years&#xD;
&#xD;
          2. The patient must be approved for transplant by the treating transplant physician. This&#xD;
             includes completion of their pretransplant workup, as directed by standard&#xD;
             Dartmouth-Hitchcock Medical Center (DHMC) Standard Operating Procedures (SOPs). DHMC&#xD;
             SOP for Pretransplant Evaluation of allogeneic recipient.&#xD;
&#xD;
          3. The patient must have a disease, listed below, with treatment responsiveness that the&#xD;
             treating transplant physician believes will benefit from an allogeneic stem cell&#xD;
             transplant. The diseases include:&#xD;
&#xD;
               1. Acute leukemia AML (Acute Myeloid Leukemia), ALL (Acute Lymphoid Leukemia)&#xD;
&#xD;
               2. Chronic leukemia CML (Chronic Myeloid Leukemia), CLL (Chronic Lymphoid Leukemia)&#xD;
&#xD;
               3. Myelodysplasia&#xD;
&#xD;
               4. Myelofibrosis&#xD;
&#xD;
               5. Lymphoma NHL (Non-Hodgkin's Lymphoma) and Hodgkin's disease&#xD;
&#xD;
               6. Plasma cell disorder, including myeloma, Waldenstrom's Macroglobulinemia&#xD;
&#xD;
          4. Donor availability- the patient must have an identified donor&#xD;
&#xD;
               1. Sibling Availability of a 6 out of 6 identical donor&#xD;
&#xD;
               2. Unrelated donor: Availability of a 6 out of 6 unrelated donor&#xD;
&#xD;
          5. No human immunodeficiency virus (HIV) infection or active hepatitis B or C&#xD;
&#xD;
          6. Easter Cooperative Oncology Group (ECOG) performance status 0, 1, or 2&#xD;
&#xD;
          7. Diffusing capacity of the lungs for carbon monoxide DLCO more than or equal to 40&#xD;
             percent predicted&#xD;
&#xD;
          8. Left ventricular ejection fraction more than or equal to 35 percent&#xD;
&#xD;
          9. Serum bilirubin less than 2x upper limit of normal transaminases less than 3x normal&#xD;
             at the time of transplant&#xD;
&#xD;
         10. No active or uncontrollable infection&#xD;
&#xD;
         11. In female, a negative pregnancy test if experiencing menstrual periods&#xD;
&#xD;
         12. No major organ dysfunction precluding transplantation&#xD;
&#xD;
         13. No evidence of an active malignancy that would limit the patient's survival to less&#xD;
             than 2 years. If there is any question, the principal investigator can make a&#xD;
             decision.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Psychiatric disorder or a mental deficiency of the patient that is sufficiently severe&#xD;
             to make compliance with the treatment unlikely, and making informed consent&#xD;
             impossible.&#xD;
&#xD;
          2. Major anticipated illness or organ failure incompatible with survival from bone marrow&#xD;
             transplant.&#xD;
&#xD;
          3. History of refractory systemic infection&#xD;
&#xD;
        Donor eligibility&#xD;
&#xD;
          1. Human leukocyte antigen (HLA) 6 out of 6 matched related or unrelated donor.&#xD;
&#xD;
          2. The donor must be healthy and must be willing to serve as a donor, based on standard&#xD;
             guidelines&#xD;
&#xD;
          3. The donor must have no significant comorbidities that would put the donor at marked&#xD;
             increased risk&#xD;
&#xD;
          4. There is no age restriction for the donor&#xD;
&#xD;
          5. Informed consent must be signed by donor, if sibling donor, or by third party if&#xD;
             unrelated donor.&#xD;
&#xD;
             Donor Exclusion Criteria&#xD;
&#xD;
          6. The National Marrow Donor Program (NMDP) guidelines for exclusion criteria will be&#xD;
             used. In addition, the following donors are NOT eligible:&#xD;
&#xD;
          7. Syngeneic donor&#xD;
&#xD;
          8. Pregnant or lactating donor&#xD;
&#xD;
          9. Human immunodeficiency virus (HIV) or active HepB or C in the donor&#xD;
&#xD;
         10. Donor unfit to receive Granulocyte-colony stimulating factor (GCSF) and undergo&#xD;
             apheresis&#xD;
&#xD;
         11. A donor with a psychiatric disorder or mental deficiency that makes compliance with&#xD;
             the procedure unlikely and informed consent impossible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Meehan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Kenneth Meehan</investigator_full_name>
    <investigator_title>Director, Bone Marrow Transplant Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

